US approves first HIV-prevention drug

Image
Press Trust of India Washington
Last Updated : Jan 24 2013 | 2:11 AM IST

The drug,'Truvada' can now be used by those at high risk of the infection and anyone who may engage in sexual activity with HIV-infected partners, the Food and Drug Administration (FDA) announced.

"In two large clinical trials, daily use of the drug was shown to significantly reduce the risk of HIV infection," it said yesterday.

However, some health workers and groups active in the HIV community opposed the approval for the once-a-day pill.

There are concerns that circulation of such a drug could engender a false sense of security and mean people will take more risks. There have also been fears that a drug-resistant strain of HIV could develop.

People diagnosed with HIV that without treatment develops into AIDS take antiviral medications to control the infection that attacks their immune system.

In a statement, the FDA stressed that the drug should be used as part of a "comprehensive HIV prevention plan", including condom use and regular HIV testing.

An advisory group of health experts recommended approval for the pill in May this year.

Truvada, is already backed by the FDA to be taken with existing antiretroviral drugs for people who have HIV.

Studies have shown that Truvada reduced the risk of HIV in healthy gay men - and among HIV-negative heterosexual partners of HIV-positive people - by between 44 per cent and 73 per cent.

"In the 80s and early 90s, HIV was viewed as a life-threatening disease; in some parts of the world it still is. Medical advances, along with the availability of close to 30 approved individual HIV drugs, have enabled us to treat it as a chronic disease most of the time," Debra Birnkrant, director of the Division of Antiviral Products at FDA, said.

"But it is still better to prevent HIV than to treat a life-long infection of HIV," she said.

Studies have shown the drug manufactured by a California-based company can reduce the risk of contracting Human immunodeficiency virus (HIV).

About 1.2 million Americans have HIV. The body

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 17 2012 | 4:35 PM IST

Next Story